Drug Trial Radar · NCT01281527
Paliperidone Palmitate Flexible Dosing in Schizophrenia
Last checked: Nov 19, 2026Latest source record: Mar 10, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,044
Actual
Start
Nov 2010
Primary completion
Nov 2012
Study completion Nov 2013
Sponsor
- Lead sponsor
- Janssen-Cilag International NVJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Jan 24, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study explores the tolerability, safety and efficacy (i.e. how well the drug works) of flexibly dosed paliperidone palmitate in the treatment of schizophrenia in patients previously unsuccessfully treated with other oral or long-acting injectable (LAI) (i.e. with a long duration of action) antipsychotics.
Conditions
- Schizophrenia
Interventions
Paliperidone PalmitateDrug
50 - 150 mg eq. every 30 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Improved efficacy for non-acute patients transitioned due to lack of efficacy, as measured by the total PANSS score at endpoint versus baseline.Time frame: Baseline to 6 months or early discontinuation
- Improved efficacy for acute patients, as measured by the total PANSS score at endpoint versus baseline.Time frame: Baseline to 6 months or early discontinuation
- Maintained efficacy for non-acute patients transitioned for other reasons based on PANSS score at endpoint versus baseline.Time frame: Baseline to 6 months or early discontinuation
Locations
127 sites in 20 countries. Site status is shown where the registry gives one.
Site not named
Salzburg, Austria
Site not named
Brussels, Belgium
Site not named
Dave, Belgium
Site not named
Diest, Belgium
Site not named
Kruishoutem, Belgium
Site not named
Liège, Belgium
Site not named
Melle, Belgium
Site not named
Roeselare, Belgium
Site not named
Sint-Denijs-Westrem, Belgium
Site not named
Tournai, Belgium
Site not named
Rijeka, Croatia
Site not named
Zagreb, Croatia
Site not named
Aalborg, Denmark
Site not named
København V, Denmark
Site not named
Randers, Denmark
Site not named
Tallinn, Estonia
Site not named
Bar-le-Duc, France
Site not named
Bron, France
Site not named
Clermont-Ferrand, France
Site not named
Dax, France
Site not named
Dijon, France
Site not named
Dole, France
Site not named
Lille, France
Site not named
Limoges, France
Site not named
Montpellier, France
Site not named
Nîmes, France
Site not named
Paris, France
Site not named
Saint-Nazaire, France
Site not named
Saint-Priest-en-Jarez, France
Site not named
Strasbourg, France
Site not named
Villejuif, France
Site not named
Bad Saarow, Germany
Site not named
Berlin, Germany
Site not named
Bielefeld, Germany
Site not named
Bochum, Germany
Site not named
Butzbach, Germany
Site not named
Dresden, Germany
Site not named
Gelsenkirchen, Germany
Site not named
Greifswald, Germany
Site not named
Hamburg, Germany
Showing 40 of 127 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.